Why Trump Is Pushing Psychedelics To Treat Mental Illness
The Trump administration is pushing to fast-track psychedelic drug approvals as his economic approval ratings hit record lows, marking a sharp reversal from his first
The Trump administration is pushing to fast-track psychedelic drug approvals as his economic approval ratings hit record lows, marking a sharp reversal from his first term stance on drugs. Three companies, Compass Pathways, Transcend Therapeutics and Usona Institute received priority FDA review vouchers under the executive order. Scientists and veterans are divided on whether the move is driven by a genuine commitment to mental health or political calculation.
Chapters 00:00 - 01:17 Introduction 01:18 - 03:49 Chapter 1: Legitimizing a new wave of drugs 03:50 - 06:20 Chapter 2: Lead with science 06:21 - 09:44 Chapter 3: Political pressure Reporting by: Brandon Gomez Produced and Shot by: Ryan Baker Edited by: Darren Geeter Animation: Jason Reginato, Alisa Stern Senior Director of Video: Lindsey Jacobson Additional Footage: Getty Images, Healing Breakthrough, Marie Phelan, Juliana Mercer » Subscribe to CNBC » Subscribe to CNBC TV About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered.
Experience special sneak peeks of your favorite shows, exclusive video and more. Want to get ahead at work? Then you need to learn how to make effective small talk. In CNBC’s new online course, How To Talk To People At Work, expert instructors teach you how to use everyday conversation to gain
visibility, build meaningful relationships and advance your career. Sign up now Connect with CNBC News Online Get the latest news Follow CNBC on Follow CNBC News on Follow CNBC News on Follow CNBC on Threads Follow CNBC News on Follow CNBC on #CNBC Why Trump Is Pushing Psychedelics To Treat Mental Illness
The BriefWire